Condizione: As New. Unread book in perfect condition.
Condizione: New.
Da: Majestic Books, Hounslow, Regno Unito
EUR 70,78
Quantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
Da: Chiron Media, Wallingford, Regno Unito
EUR 63,86
Quantità: 2 disponibili
Aggiungi al carrellopaperback. Condizione: New.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 66,81
Quantità: 10 disponibili
Aggiungi al carrelloCondizione: New.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 67,21
Quantità: 10 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
Da: Revaluation Books, Exeter, Regno Unito
EUR 78,85
Quantità: 2 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. 9.18x6.12 inches. In Stock.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 82,88
Quantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
Da: THE SAINT BOOKSTORE, Southport, Regno Unito
EUR 76,55
Quantità: Più di 20 disponibili
Aggiungi al carrelloPaperback / softback. Condizione: New. New copy - Usually dispatched within 4 working days.
Condizione: New.
Da: Rarewaves.com USA, London, LONDO, Regno Unito
EUR 101,86
Quantità: Più di 20 disponibili
Aggiungi al carrelloHardback. Condizione: New.
Da: CitiRetail, Stevenage, Regno Unito
EUR 71,41
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: new. Paperback. Drug development is at a crossroads. As personalized medicine and targeted therapies expand, traditional clinical trial models have become too slow, costly, and inefficient. To meet the urgent need for faster, reliable evidence generation and decision making, researchers and regulators alike have turned to innovative trial designs. Among these, master protocols stand out as a transformative approach, allowing multiple therapies, disease subtypes, or objectives to be studied under a single, integrated framework. Proven successful in oncology, COVID-19, and beyond, they improve efficiency, reduce participant exposure to ineffective treatments, and accelerate meaningful outcomes with patient centric approach, prompting regulatory guidance and global adoption.This book provides a multidisciplinary exploration of master protocol clinical trials, blending clinical, statistical, regulatory, operational, economic insights and patients perspectives. It examines both opportunities and challenges in design and implementation, and provides in-depth summary and discussion on real-world examples such as I-SPY, ROAR, and RECOVERY. A practical guide for researchers, statisticians, regulators, and industry professionals, it demonstrates how master protocols can reshape drug development and bring innovative therapies to patients faster. Provides comprehensive, theoretical and practical aspects for master protocol trials Includes most recent development in the master protocol clinical trials Covers broad topics such as trial designs, governance oversight, software implementation, database and data pipeline, multi-regional trials, risk and benefit with operational solutions, economic considerations, regulatory perspectives, patient engagement and diversity Deep dives into numerous real world case studies, their underlying thinking, challenges and success. Includes global perspective in multi-regional clinical development This book provides a multidisciplinary exploration of master protocol clinical trials, blending clinical, statistical, regulatory, operational, economic insights and patients perspectives. It examines both opportunities and challenges in design and implementation, and provides in-depth summary and discussion on real-world examples. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
EUR 72,39
Quantità: 2 disponibili
Aggiungi al carrelloCondizione: New. Ruixiao LuDr. Ruixiao Lu is a recognized leader in the biotech and biopharma industry, currently serving as Vice President, Head of Biostatistics & Statistical Programming at Alumis Inc. She has held senior leadership roles at various c.
Lingua: Inglese
Editore: Taylor & Francis Ltd Mai 2026, 2026
ISBN 10: 1032544546 ISBN 13: 9781032544540
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 74,24
Quantità: 2 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Neuware - Drug development is at a crossroads. As personalized medicine and targeted therapies expand, traditional clinical trial models have become too slow, costly, and inefficient. To meet the urgent need for faster, reliable evidence generation and decision making, researchers and regulators alike have turned to innovative trial designs. Among these, master protocols stand out as a transformative approach, allowing multiple therapies, disease subtypes, or objectives to be studied under a single, integrated framework. Proven successful in oncology, COVID-19, and beyond, they improve efficiency, reduce participant exposure to ineffective treatments, and accelerate meaningful outcomes with patient centric approach, prompting regulatory guidance and global adoption.
Da: preigu, Osnabrück, Germania
EUR 80,85
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Master Protocol Clinical Trials for Evidence Generation | Strategies, Designs, Operations, and Case Studies | Chengxing Lu (u. a.) | Taschenbuch | Chapman & Hall/CRC Biostatistics Series | Einband - flex.(Paperback) | Englisch | 2026 | Taylor & Francis Ltd | EAN 9781032544540 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu.
Da: AussieBookSeller, Truganina, VIC, Australia
EUR 134,54
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: new. Paperback. Drug development is at a crossroads. As personalized medicine and targeted therapies expand, traditional clinical trial models have become too slow, costly, and inefficient. To meet the urgent need for faster, reliable evidence generation and decision making, researchers and regulators alike have turned to innovative trial designs. Among these, master protocols stand out as a transformative approach, allowing multiple therapies, disease subtypes, or objectives to be studied under a single, integrated framework. Proven successful in oncology, COVID-19, and beyond, they improve efficiency, reduce participant exposure to ineffective treatments, and accelerate meaningful outcomes with patient centric approach, prompting regulatory guidance and global adoption.This book provides a multidisciplinary exploration of master protocol clinical trials, blending clinical, statistical, regulatory, operational, economic insights and patients perspectives. It examines both opportunities and challenges in design and implementation, and provides in-depth summary and discussion on real-world examples such as I-SPY, ROAR, and RECOVERY. A practical guide for researchers, statisticians, regulators, and industry professionals, it demonstrates how master protocols can reshape drug development and bring innovative therapies to patients faster. Provides comprehensive, theoretical and practical aspects for master protocol trials Includes most recent development in the master protocol clinical trials Covers broad topics such as trial designs, governance oversight, software implementation, database and data pipeline, multi-regional trials, risk and benefit with operational solutions, economic considerations, regulatory perspectives, patient engagement and diversity Deep dives into numerous real world case studies, their underlying thinking, challenges and success. Includes global perspective in multi-regional clinical development This book provides a multidisciplinary exploration of master protocol clinical trials, blending clinical, statistical, regulatory, operational, economic insights and patients perspectives. It examines both opportunities and challenges in design and implementation, and provides in-depth summary and discussion on real-world examples. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.
Condizione: As New. Unread book in perfect condition.
Da: Rarewaves.com UK, London, Regno Unito
EUR 95,88
Quantità: Più di 20 disponibili
Aggiungi al carrelloPaperback. Condizione: New.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 171,43
Quantità: 10 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
Condizione: New.
Da: Majestic Books, Hounslow, Regno Unito
EUR 183,58
Quantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 194,84
Quantità: 10 disponibili
Aggiungi al carrelloCondizione: New.
Condizione: New.
EUR 170,17
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. Ruixiao LuDr. Ruixiao Lu is a recognized leader in the biotech and biopharma industry, currently serving as Vice President, Head of Biostatistics & Statistical Programming at Alumis Inc. She has held senior leadership roles at various c.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 208,59
Quantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
Lingua: Inglese
Editore: Taylor & Francis Ltd Mai 2026, 2026
ISBN 10: 103254452X ISBN 13: 9781032544526
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 211,90
Quantità: 2 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. Neuware - Drug development is at a crossroads. As personalized medicine and targeted therapies expand, traditional clinical trial models have become too slow, costly, and inefficient. To meet the urgent need for faster, reliable evidence generation and decision making, researchers and regulators alike have turned to innovative trial designs. Among these, master protocols stand out as a transformative approach, allowing multiple therapies, disease subtypes, or objectives to be studied under a single, integrated framework. Proven successful in oncology, COVID-19, and beyond, they improve efficiency, reduce participant exposure to ineffective treatments, and accelerate meaningful outcomes with patient centric approach, prompting regulatory guidance and global adoption.
Da: Grand Eagle Retail, Bensenville, IL, U.S.A.
Paperback. Condizione: new. Paperback. Drug development is at a crossroads. As personalized medicine and targeted therapies expand, traditional clinical trial models have become too slow, costly, and inefficient. To meet the urgent need for faster, reliable evidence generation and decision making, researchers and regulators alike have turned to innovative trial designs. Among these, master protocols stand out as a transformative approach, allowing multiple therapies, disease subtypes, or objectives to be studied under a single, integrated framework. Proven successful in oncology, COVID-19, and beyond, they improve efficiency, reduce participant exposure to ineffective treatments, and accelerate meaningful outcomes with patient centric approach, prompting regulatory guidance and global adoption.This book provides a multidisciplinary exploration of master protocol clinical trials, blending clinical, statistical, regulatory, operational, economic insights and patients perspectives. It examines both opportunities and challenges in design and implementation, and provides in-depth summary and discussion on real-world examples such as I-SPY, ROAR, and RECOVERY. A practical guide for researchers, statisticians, regulators, and industry professionals, it demonstrates how master protocols can reshape drug development and bring innovative therapies to patients faster. Provides comprehensive, theoretical and practical aspects for master protocol trials Includes most recent development in the master protocol clinical trials Covers broad topics such as trial designs, governance oversight, software implementation, database and data pipeline, multi-regional trials, risk and benefit with operational solutions, economic considerations, regulatory perspectives, patient engagement and diversity Deep dives into numerous real world case studies, their underlying thinking, challenges and success. Includes global perspective in multi-regional clinical development This book provides a multidisciplinary exploration of master protocol clinical trials, blending clinical, statistical, regulatory, operational, economic insights and patients perspectives. It examines both opportunities and challenges in design and implementation, and provides in-depth summary and discussion on real-world examples. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
Da: Grand Eagle Retail, Bensenville, IL, U.S.A.
Hardcover. Condizione: new. Hardcover. Special Issue 'Additive Manufacturing of Fibre-Reinforced Polymer Composites' has 13 pioneering studies advancing AM-FRPCs. Covering aerospace, automotive, energy, sustainability, it presents integration of novel materials, process/structural innovations, smart functionalities. It shows AM enables complex geometries, multifunctional parts with tailored mechanical, thermal, sensing properties. Articles address interlaminar toughness, porosity, fibre misalignment via nano-fillers, hybrid reinforcements, optimised paths. The highlights include laser-induced graphene for real-time damage sensing; eco-friendly biocomposites (chem-treated natural fibres); and spatial 3D printing for low-density, high-strength trusses. Mechanical testing uses experimental/numerical methods: acoustic emission, digital image correlation, finite element simulation, and Taguchi optimisation. Integrating AI and neural networks in print tuning and performance prediction marks a shift to intelligent manufacturing. From boosting buckling in anisotropic grids to refining laser-sintering via thermal simulation, this Special Issue offers insights into current research and future opportunities in process control, defect mitigation, and in situ monitoring. It is a timely collection of scientific breakthroughs and engineering practices driving next-gen FRPCs via AM, aiding researchers, engineers, and designers using AM's unique high-performance composite advantages. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
Da: PBShop.store US, Wood Dale, IL, U.S.A.
EUR 80,83
Quantità: Più di 20 disponibili
Aggiungi al carrelloHRD. Condizione: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Da: PBShop.store UK, Fairford, GLOS, Regno Unito
EUR 74,90
Quantità: Più di 20 disponibili
Aggiungi al carrelloHRD. Condizione: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.